Access to treatment and survival outcomes among US veterans with stage I non–small cell lung cancer (NSCLC) may vary depending on demographic and sociological patterns, according to a study presented at the 2025 ASCO Annual Meeting. Read More ›
he median progression-free survival was 11.14 months with ivonescimab and 5.85 months with pembrolizumab (Hazard Ratio [HR], 0.51; 95% CI, 0.38-0.69; P NSCLC, and patients with brain metastases. Read More ›
For this Interview with the Innovators series, several interviews were conducted with executives and scientists from Genmab, an international biotech company with 24 years of experience in developing cutting- edge antibodies and antibody technology. Read More ›
